Global tuberculosis drug development pipeline: the need and the reality - The Lancet
Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target | Future Medicinal Chemistry
New therapeutics in development and future directions | Current & Emerging Diagnostics, Therapeutics & Vaccines for Tuberculosis
SQ109 mechanism of action The figure depicts stylized components of the... | Download Scientific Diagram
APExBIO - SQ109|Antibiotic for treatment of pulmonary T|CAS# 502487-67-4
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. | Semantic Scholar
SQ109 | CAS:502487-67-4 | Antibiotic for treatment of pulmonary T | High Purity | Manufacturer BioCrick
SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis | Antimicrobial Agents and Chemotherapy
Hydroxylation of antitubercular drug candidate, SQ109, by mycobacterial cytochrome P450 | bioRxiv
Hydroxylation of antitubercular drug candidate, SQ109, by mycobacterial cytochrome P450 | bioRxiv
TB R&D Update: Tuberculosis drug, SQ109, targets multiple enzymes and could treat other diseases while preventing resistance | Working Group for New TB Drugs
Strategies towards the synthesis of anti-tuberculosis drugs - Organic & Biomolecular Chemistry (RSC Publishing) DOI:10.1039/C9OB00817A
SQ109 activity compared with ethambutol in the standard drug regimen... | Download Scientific Diagram
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. - Abstract - Europe PMC
SQ109 | Infectex
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. - Abstract - Europe PMC
SQ109, a new drug lead for Chagas disease. - Abstract - Europe PMC
SQ109 mechanism of action The figure depicts stylized components of the... | Download Scientific Diagram
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects - The Lancet Infectious Diseases
SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis | Antimicrobial Agents and Chemotherapy
SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis | Antimicrobial Agents and Chemotherapy
Direct Inhibition of MmpL3 by Novel Antitubercular Compounds | ACS Infectious Diseases
Tuberculosis Drugs and Mechanisms of Action | NIH: National Institute of Allergy and Infectious Diseases
Proposed sites of action of SQ109 and its analogues. MenA, MenG... | Download Scientific Diagram
